Browsing Radiotherapy and Imaging by author "James, Nicholas"
Now showing items 41-60 of 63
-
Patients choose certainty over burden in bladder cancer surveillance.
van Osch, FHM; Nekeman, D; Aaronson, NK; Billingham, LJ; James, ND; et al. (SPRINGER, 2019-12-01)BACKGROUND: Due to the high risk of recurrence of non-muscle invasive bladder cancer, all patients undergo regular cystoscopic surveillance for early detection. As cystoscopy is invasive, costly and increases the burden ... -
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.
Pezaro, CJ; Omlin, A; Mastris, K; ANZUP Consumer Advisory Panel,; Attard, G; et al. (OXFORD UNIV PRESS, 2017-08-01) -
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Sternberg, CN; Loriot, Y; James, N; Choy, E; Castellano, D; et al. (ELSEVIER SCIENCE BV, 2019-07-01)BACKGROUND: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a broader, pretreated population, including patients ... -
Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection.
Baxter, L; Gordon, NS; Ott, S; Wang, J; Patel, P; et al. (NATURE PORTFOLIO, 2023-01-19)Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74, TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could function as biomarkers for the non-invasive detection of ... -
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.
Burdett, S; Boevé, LM; Ingleby, FC; Fisher, DJ; Rydzewska, LH; et al. (ELSEVIER, 2019-07-01)BACKGROUND: Many trials are evaluating therapies for men with metastatic hormone-sensitive prostate cancer (mHSPC). OBJECTIVE: To systematically review trials of prostate radiotherapy. DESIGN, SETTING, AND PARTICIPANTS: ... -
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Rush, HL; Murphy, L; Morgans, AK; Clarke, NW; Cook, AD; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-03-10)PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic ... -
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Parker, CC; James, ND; Brawley, CD; Clarke, NW; Hoyle, AP; et al. (ELSEVIER SCIENCE INC, 2018-12-01)BACKGROUND: Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostate cancer, and that the benefit would be greatest in patients with a low ... -
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Parker, CC; James, ND; Brawley, CD; Clarke, NW; Ali, A; et al. (PUBLIC LIBRARY SCIENCE, 2022-06-01)BACKGROUND: STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden ... -
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Sternberg, C; Armstrong, A; Pili, R; Ng, S; Huddart, R; et al. (AMER SOC CLINICAL ONCOLOGY, 2016-08-01)PURPOSE: Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant ... -
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; De Bono, JS; et al. (Elsevier BV, 2015-06-01) -
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
Ward, DG; Gordon, NS; Boucher, RH; Pirrie, SJ; Baxter, L; et al. (WILEY, 2019-09-01)OBJECTIVES: To develop a focused panel of somatic mutations (SMs) present in the majority of urothelial bladder cancers (UBCs), to investigate the diagnostic and prognostic utility of this panel, and to compare the ... -
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
Neal, DE; Metcalfe, C; Donovan, JL; Lane, JA; Davis, M; et al. (ELSEVIER, 2020-03-01)BACKGROUND: The ProtecT trial reported intention-to-treat analysis of men with localised prostate cancer (PCa) randomly allocated to active monitoring (AM), radical prostatectomy, and external beam radiotherapy. OBJECTIVE: ... -
The association between smoking cessation before and after diagnosis and non-muscle-invasive bladder cancer recurrence: a prospective cohort study.
van Osch, FHM; Jochems, SHJ; Reulen, RC; Pirrie, SJ; Nekeman, D; et al. (SPRINGER, 2018-07-01)BACKGROUND: Smoking is a major risk factor for bladder cancer, but the relationship between smoking cessation after initial treatment and bladder cancer recurrence has been investigated less frequently and not prospectively ... -
The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".
Ali, A; Hoyle, AP; Parker, CC; Brawley, CD; Cook, A; et al. (ELSEVIER, 2020-08-01)BACKGROUND: Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, ... -
The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
Choudhury, A; West, CM; Porta, N; Hall, E; Denley, H; et al. (ELSEVIER SCI LTD, 2017-02-28)BACKGROUND: Severe chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from ... -
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Schiavone, F; Bathia, R; Letchemanan, K; Masters, L; Amos, C; et al. (BMC, 2019-05-29)BACKGROUND: There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons ... -
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
Parker, CC; Coleman, RE; Sartor, O; Vogelzang, NJ; Bottomley, D; et al. (ELSEVIER SCIENCE BV, 2018-03-01)BACKGROUND: In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone ... -
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Parker, CC; Clarke, NW; Cook, AD; Kynaston, HG; Petersen, PM; et al. (ELSEVIER SCIENCE INC, 2020-10-31)BACKGROUND: The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage ... -
Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation.
Russo, IJ; Ju, Y; Gordon, NS; Zeegers, MP; Cheng, KK; et al. (IOS PRESS, 2018-01-20)BACKGROUND: TERT promotor mutations are present in >75% of bladder tumours; these mutations are also detectable in urine. Previous studies have used urinary pellet DNA, and semi-quantitative methods unsuitable for detecting ... -
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James, N; Pirrie, S; Pope, A; Barton, D; Andronis, L; et al. (NIHR JOURNALS LIBRARY, 2016-07-01)BACKGROUND: Bony metastatic castration-refractory prostate cancer is associated with a poor prognosis and high morbidity. TRAPEZE was a two-by-two factorial randomised controlled trial of zoledronic acid (ZA) and strontium-89 ...